BioHarvest SciencesBHST -3.50%63 Receivables Turnover is 4.15 as of Mar. 2026. GuruFocus rates BHST with a GF Score™ of 63/100 and a GF Value™ of $8.58 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,936 Consumer Packaged Goods companies, BioHarvest Sciences ranks better than 80.84% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BioHarvest Sciences's Revenue for the
three
months ended in Mar. 2026 was $8.51 Mil. BioHarvest Sciences's average Accounts Receivable for the
three
months ended in Mar. 2026 was $2.05 Mil.
Hence, BioHarvest Sciences's Receivables Turnover for the
three
months ended in Mar. 2026 was 4.15.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
BioHarvest Sciences Receivables Turnover Related Terms
BioHarvest Sciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for BioHarvest Sciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BHST vs BRID, BOF, BFNH: Receivables Turnover Comparison
For the Packaged Foods subindustry, BioHarvest Sciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioHarvest Sciences Receivables Turnover vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, BioHarvest Sciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where BioHarvest Sciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioHarvest Sciences (BHST) has a Receivables Turnover of 4.15 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BioHarvest Sciences and its competitors. According to the industry distribution chart, BioHarvest Sciences ranks #371 out of 1936 companies in the Consumer Packaged Goods industry, placing it in the top 19.2%.
Is BioHarvest Sciences' Receivables Turnover too high?
BioHarvest Sciences' current Receivables Turnover is 4.15. The Consumer Packaged Goods industry median Receivables Turnover is 9.38. BioHarvest Sciences' value of 4.15 is 55.8% below this industry median. Based on the distribution chart, BioHarvest Sciences ranks #371 out of 1936 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, BioHarvest Sciences has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioHarvest Sciences' Receivables Turnover compare to BRID and BOF?
According to the Consumer Packaged Goods industry distribution chart, BioHarvest Sciences ranks #371 out of 1936 companies for Receivables Turnover. This places BioHarvest Sciences in the top 19% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 9.38. BioHarvest Sciences' value of 4.15 is 55.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Consumer Packaged Goods company?
The median Receivables Turnover among Consumer Packaged Goods companies is 9.38, based on 1,936 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioHarvest Sciences's current Receivables Turnover of 4.15 is 55.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BioHarvest Sciences and its competitors. For the Consumer Packaged Goods industry, the median Receivables Turnover is 9.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioHarvest Sciences's current Receivables Turnover is 4.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioHarvest Sciences stock overvalued right now?
Based on GuruFocus' analysis, BioHarvest Sciences (BHST) is currently considered Possible Value Trap. The stock's GF Value™ is $8.58, compared to a current price of $2.76 — trading 67.8% below its estimated fair value. The current Receivables Turnover is 4.15 and 55.8% below the Consumer Packaged Goods industry median of 9.38. BioHarvest Sciences' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For BioHarvest Sciences (BHST), the current Receivables Turnover is 4.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioHarvest Sciences (BHST) Overvalued in 2026?
Based on GuruFocus' analysis, BioHarvest Sciences stock appears to be undervalued.
The current stock price of $2.76 is trading 67.8% below its estimated GF Value™ of $8.58.
GuruFocus considers BioHarvest Sciences to be Possible Value Trap.
Key valuation signals for BHST:
Receivables Turnover: 4.15
GF Value™: $8.58 vs. price of $2.76 (67.8% below fair value)
Industry Position: 55.8% below the Consumer Packaged Goods median (#371 of 1936)
No single metric tells the full story. See the BHST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
63GF Score
Get the complete analysis for BHST
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHST has been successfully added to your 
